ARS Pharmaceuticals (SPRY) News Today $14.02 +0.02 (+0.14%) (As of 12/6/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Research Analysts Issue Forecasts for SPRY FY2024 EarningsDecember 7 at 1:13 AM | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Justin Chakma Sells 50,000 SharesARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Justin Chakma sold 50,000 shares of the firm's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $14.23, for a total value of $711,500.00. Following the sale, the insider now owns 136,380 shares of the company's stock, valued at $1,940,687.40. The trade was a 26.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.December 6 at 7:57 PM | marketbeat.comCantor Fitzgerald Analysts Lower Earnings Estimates for SPRYARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2024 earnings per share estimates for ARS Pharmaceuticals in a research report issued on Wednesday, December 4th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the companyDecember 6 at 8:22 AM | marketbeat.comWexford Capital LP Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Wexford Capital LP acquired a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 248,347 shares of the company's stock, valued at approximately $3,601,000. WDecember 6 at 8:22 AM | marketbeat.comJacobs Levy Equity Management Inc. Buys 288,021 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Jacobs Levy Equity Management Inc. grew its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 78.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 653,048 shares of the company's stock after purcDecember 6 at 5:10 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $203,115.00 in StockDecember 5 at 7:13 AM | insidertrades.comARS Pharmaceuticals announces planned launch of neffyinSchoolsDecember 5 at 4:09 AM | markets.businessinsider.comARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No CostDecember 4, 2024 | globenewswire.comMiura Global Management LLC Takes $3.92 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Miura Global Management LLC bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 270,000 shares of the company's stock, valued atDecember 4, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Buy" from AnalystsDecember 3, 2024 | americanbankingnews.comBrokerages Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Price Target at $24.00December 1, 2024 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $359,750.00 in StockNovember 28, 2024 | insidertrades.comConnor Clark & Lunn Investment Management Ltd. Purchases Shares of 77,208 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Connor Clark & Lunn Investment Management Ltd. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 77,208 shares of the company's sNovember 28, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Buy" from AnalystsARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating onNovember 28, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Rating of "Buy" by AnalystsShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have received a consensus recommendation of "Buy" from the six research firms that are presently covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a buy rating and two have issued a strong buy ratiNovember 28, 2024 | marketbeat.comARS Pharmaceuticals: Demand Curve Is Key UnknownNovember 20, 2024 | seekingalpha.comFirst Turn Management LLC Takes $8.60 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)First Turn Management LLC bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 593,291 shares of the company's stock, valued at approximNovember 19, 2024 | marketbeat.comWhat is Leerink Partnrs' Forecast for SPRY FY2024 Earnings?ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities researchers at Leerink Partnrs lowered their FY2024 EPS estimates for shares of ARS Pharmaceuticals in a report issued on Wednesday, November 13th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.70) per sNovember 18, 2024 | marketbeat.comWilliam Blair Analysts Increase Earnings Estimates for SPRYARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at William Blair raised their FY2024 earnings estimates for ARS Pharmaceuticals in a research report issued on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings perNovember 18, 2024 | marketbeat.comRoyce & Associates LP Purchases 45,755 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Royce & Associates LP increased its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 691,455 shares of the company's stock afterNovember 17, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for SPRY FY2027 Earnings?ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at Leerink Partnrs lowered their FY2027 earnings per share (EPS) estimates for ARS Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst R. Ruiz now expects that the company willNovember 15, 2024 | marketbeat.comQ4 EPS Estimate for ARS Pharmaceuticals Boosted by AnalystARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Research analysts at William Blair boosted their Q4 2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a research report issued on Wednesday, November 13th. William Blair analyst L. Hanbury-Brown now forecasts thatNovember 15, 2024 | marketbeat.comARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...November 14, 2024 | finance.yahoo.comARS Pharmaceuticals’ Strong Q3 2024 HighlightsNovember 14, 2024 | markets.businessinsider.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comJames E. Flynn Sells 528,456 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockNovember 14, 2024 | insidertrades.comGSA Capital Partners LLP Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)GSA Capital Partners LLP grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 67.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 98,900 shares of the company's stock afterNovember 14, 2024 | marketbeat.comLeerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)November 14, 2024 | markets.businessinsider.comARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 13, 2024 | globenewswire.comARS Pharmaceuticals announces agreement with ALK to commercialize neffyNovember 11, 2024 | markets.businessinsider.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week High - Time to Buy?ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month High - What's Next?November 11, 2024 | marketbeat.comARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024November 11, 2024 | benzinga.comARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United StatesNovember 11, 2024 | globenewswire.comALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)November 9, 2024 | globenewswire.comARS Pharmaceuticals (SPRY) Set to Announce Quarterly Earnings on WednesdayARS Pharmaceuticals (NASDAQ:SPRY) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming ConferencesNovember 6, 2024 | finance.yahoo.comWilliam Blair Has Positive Outlook for SPRY FY2024 EarningsARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities researchers at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a report issued on Monday, November 4th. William Blair analyst L. Hanbury-Brown now anticipates that the companyNovember 6, 2024 | marketbeat.comRaymond James & Associates Buys New Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Raymond James & Associates bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 204,783 shares of the company's stock, valued at approximately $2,969,000. RaymNovember 5, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by AnalystsShares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) have been given a consensus recommendation of "Buy" by the six analysts that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the cNovember 3, 2024 | marketbeat.comCantor Fitzgerald healthcare analyst holds an analyst/industry conference callNovember 1, 2024 | markets.businessinsider.comAllspring Global Investments Holdings LLC Invests $2.58 Million in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)Allspring Global Investments Holdings LLC bought a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 178,221 shares of theOctober 30, 2024 | marketbeat.comARS Pharmaceuticals showcases intranasal epinephrine data at ACAAI meetingOctober 25, 2024 | markets.businessinsider.comARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific MeetingOctober 24, 2024 | globenewswire.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 5% - Should You Sell?ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5% - Here's What HappenedOctober 23, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 12-Month High - What's Next?ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 1-Year High - Time to Buy?October 22, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.3% - Should You Buy?ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.3% - Still a Buy?October 21, 2024 | marketbeat.comHere's Why We're Not At All Concerned With ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn SituationOctober 19, 2024 | finance.yahoo.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott Sells 12,500 SharesOctober 18, 2024 | insidertrades.comKathleen D. Scott Sells 12,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) CFO Kathleen D. Scott sold 12,500 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $16.00, for a total transaction of $200,000.00. Following the sale, the chief financial officer now directly owns 4,949 shares of the company's stock, valued at approximately $79,184. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.October 17, 2024 | marketbeat.com Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier. Including the name of the #1 company to buy. SPRY Media Mentions By Week SPRY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼-0.070.68▲Average Medical News Sentiment SPRY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼174▲SPRY Articles Average Week Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACLX News Today BBIO News Today RNA News Today ADMA News Today BHVN News Today RARE News Today APLS News Today IMVT News Today OGN News Today PTCT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 12/8/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredUrgent warning about your moneyThe stock market is booming … And Bitcoin just hiked through the roof. But don't get fooled by the "good...Weiss Ratings | SponsoredElon declares war on company he co-founded!?Elon Musk is leading humanity into the new era of AI. He’s just received a fresh $6 billion in funding for ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
